PDC and non-small cell lung carcinoma: It is important to remark, however, that although our study provided evidence that the pDC, slan+-monocyte and NK cell numbers may function as predictive biomarkers of ICI monotherapy in NSCLC patients, a rigorous analytical and clinical validation across a large patient cohort is needed to define the optimal cut-off values that could potentially be used in clinical practice.